Tag: Pascal Soriot
Executive pay debate intensifies with proxy advisors in the firing line
Big pharma chair Michel Demaré points to proxy advisors as cause of block on higher pay while more FTSE 100 companies plan boost to packages.
AstraZeneca shareholders signal concerns over pay
Almost 40% of AstraZeneca shareholders deliver a blow to the pharmaceuticals company, by voting against its annual remuneration report.